After radical hysterectomy and pelvic lymphadenectomy for early-stage cervical cancer, patients often face a critical decision: whether to undergo adjuvant therapy. The goal of treatment—typically radiation therapy (RT) alone or combined with chemotherapy (CRT)—is to lower the risk of cancer recurrence.
However, these therapies carry significant side effects. Patients may experience fatigue, nausea, anemia, and neutropenia. Radiation can irritate the gastrointestinal tract, causing diarrhea, cramping, and changes in bowel habits. Bladder irritation, increased urinary frequency, and mild discomfort may also occur. Sexual health can be affected, with vaginal dryness, narrowing, or pain during intercourse impacting intimacy and emotional well-being.
Beyond physical symptoms, emotional stress and disruptions in daily life are common. Anxiety about recurrence, lingering fatigue, and difficulty resuming work or family responsibilities can weigh heavily. For instance, a young mother undergoing CRT reported that even mild nausea and fatigue interfered with work and family duties, adding emotional strain.
Exploring Adjuvant Therapy Options for Intermediate-Risk Cervical Cancer
Historically, RT alone has been standard for patients with intermediate-risk cervical cancer, defined by tumor size, depth of invasion, and lymphovascular involvement (Sedlis criteria). To determine whether outcomes could improve, the NRG Oncology/GOG-0263/KGOG 1008 trial (NCT01101451) evaluated weekly cisplatin-based CRT versus RT alone. Findings were published in Annals of Oncology.
This phase 3, open-label trial enrolled adults with stage IB–IIA cervical cancer and intermediate-risk features. Eligible histologies included squamous cell carcinoma, adeno-squamous carcinoma, and adenocarcinoma. Participants were randomized 1:1 to RT alone (n = 158) or CRT (n = 158). RT was delivered via 3D conformal therapy or intensity-modulated radiation therapy (IMRT) at a total dose of 50.4 Gy over 28 fractions. CRT patients also received weekly cisplatin (40 mg/m²).
Baseline labs confirmed adequate blood, kidney, and liver function. Patients with high-risk features, prior therapy, or recent malignancies were excluded. Follow-up included physical exams, Pap tests, imaging, and quality-of-life assessments using the FACT-Cx questionnaire. The primary endpoint was recurrence-free survival (RFS), with overall survival (OS) and quality of life as secondary endpoints.
Among 316 analyzed patients (median age 46), most had stage IB1 disease and squamous cell carcinoma (56%). Nearly all RT-only patients (99.4%) completed planned therapy, compared with 84.8% of CRT patients.
After a median follow-up of 76.5 months, the 3-year RFS was slightly higher in the CRT group (88.5%) than RT alone (85.4%), though not statistically significant (HR 0.698, P = .09). OS trended in favor of CRT but did not reach significance (HR 0.586, P = .07). Recurrence patterns were similar. Subgroup analysis suggested CRT may benefit patients receiving conventional RT, whereas IMRT appeared to favor RT alone.
Patients receiving CRT experienced higher rates of severe hematologic adverse events (42.9% vs. 15.3% in RT; P < .01). Patient-reported outcomes showed temporary declines in quality of life during CRT, generally returning to baseline by 36 weeks.
Nursing Considerations
For the young mother in our example, trial results provided context on treatment benefits and risks. Adding cisplatin offered modest improvements in 3-year RFS and a trend toward better OS, but also increased severe hematologic side effects and temporarily reduced quality of life.
Nurses play a key role in translating these findings into patient care. They can monitor blood counts, manage nausea, and provide strategies to address fatigue. Support may include planning work flexibility, arranging family assistance, and normalizing emotional reactions. By applying trial data to individual cases, nurses help patients make informed decisions, anticipate challenges, and feel supported throughout treatment and recovery.
Related topic：
